These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 35229286)

  • 1. Heterogeneity of enrolment criteria for ongoing smouldering myeloma trials.
    Soomro MA; Hoffman J; Goodman AM; Sborov DW; Mohyuddin GR
    Br J Haematol; 2022 Jun; 197(6):e86-e88. PubMed ID: 35229286
    [No Abstract]   [Full Text] [Related]  

  • 2. The difficult business of assessing new therapies for smouldering multiple myeloma.
    Zonder JA
    Br J Haematol; 2018 Aug; 182(4):463-464. PubMed ID: 29767407
    [No Abstract]   [Full Text] [Related]  

  • 3. Applying current smouldering myeloma risk models to a UK single-centre cohort and clinical features at progression.
    Ainley L; Camilleri M; Chavda SJ; McMillan A; Lee L; Popat R; Sillito F; Yong K
    Br J Haematol; 2022 Mar; 196(6):e63-e66. PubMed ID: 34812509
    [No Abstract]   [Full Text] [Related]  

  • 4. Serum markers alone can define high-risk smouldering multiple myeloma: new insights from the Czech Myeloma Group model.
    Sørrig R
    Br J Haematol; 2020 Jul; 190(2):137-138. PubMed ID: 32220013
    [No Abstract]   [Full Text] [Related]  

  • 5. Survival in smouldering myeloma and symptomatic myeloma: Is there an emerging Will Rogers phenomenon?
    Chakraborty R
    Eur J Cancer; 2022 Sep; 172():234-236. PubMed ID: 35797760
    [No Abstract]   [Full Text] [Related]  

  • 6. Burning questions about smouldering myeloma.
    DeWeerdt S
    Nature; 2020 Nov; 587(7835):S58-S59. PubMed ID: 33239807
    [No Abstract]   [Full Text] [Related]  

  • 7. Smoldering Myeloma and the Art of War.
    Lonial S; Dhodapkar MV; Rajkumar SV
    J Clin Oncol; 2020 Jul; 38(21):2363-2365. PubMed ID: 32463739
    [No Abstract]   [Full Text] [Related]  

  • 8. Regression of smoldering myeloma with treatment of Gaucher disease.
    Barley K; Parekh A; Salam S; Mendu DR; Shukla RP; Vatti D; Verina D; Stauffer C; Salib C; El Jamal S; Teruya-Feldstein J; Duffield AS; Leshchenko VV; Jagannath S; Balwani M; Parekh S
    Blood Adv; 2024 Apr; 8(7):1634-1638. PubMed ID: 38285963
    [No Abstract]   [Full Text] [Related]  

  • 9. Early intervention effective in smouldering multiple myeloma.
    Gourd E
    Lancet Oncol; 2019 Dec; 20(12):e666. PubMed ID: 31679982
    [No Abstract]   [Full Text] [Related]  

  • 10. Early treatment for high-risk smouldering myeloma: has the time come?
    Ludwig H
    Lancet Oncol; 2016 Aug; 17(8):1030-1032. PubMed ID: 27402144
    [No Abstract]   [Full Text] [Related]  

  • 11. The landscape of trials for smoldering multiple myeloma: endpoints, trial design, and lessons learnt.
    Mohyuddin GR; Ouchveridze E; Goodman A; Prasad V
    Leuk Lymphoma; 2021 Nov; 62(11):2793-2795. PubMed ID: 34114943
    [No Abstract]   [Full Text] [Related]  

  • 12. Smoldering multiple myeloma: biology, clinical manifestations and management.
    Nsiala L; Bobin A; Levy A; Gruchet C; Sabirou F; Gardeney H; Cailly L; Manier S; Moya N; Tomowiak C; Guidez S; Leleu X; Decaux O
    Leuk Lymphoma; 2022 Mar; 63(3):518-529. PubMed ID: 34672244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. State of the science in smoldering myeloma: Should we be treating in the clinic?
    Hill E; Dew A; Kazandjian D
    Semin Oncol; 2019 Apr; 46(2):112-120. PubMed ID: 31072611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis and Management of Monoclonal Gammopathy and Smoldering Multiple Myeloma.
    Schmidt T; Callander N
    J Natl Compr Canc Netw; 2020 Dec; 18(12):1720-1729. PubMed ID: 33347744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shall we treat smoldering multiple myeloma in the near future?
    Landgren O
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):194-204. PubMed ID: 29222256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients.
    González-Calle V; Mateos MV
    Eur J Intern Med; 2018 Dec; 58():57-63. PubMed ID: 29907380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Smoldering multiple myeloma 40 years later: a story of unintended disease.
    Yavorkovsky LL
    Expert Rev Hematol; 2021 Feb; 14(2):149-153. PubMed ID: 33430658
    [No Abstract]   [Full Text] [Related]  

  • 18. Identification of
    Garcia JB; Storti P; Iannozzi NT; Marchica V; Agnelli L; Toscani D; Franceschi V; Todaro G; Sammarelli G; Notarfranchi L; Scita M; Palma BD; Raimondi V; Lungu O; Pruneri G; Donofrio G; Giuliani N
    Haematologica; 2024 Feb; 109(2):627-631. PubMed ID: 37608776
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of low-dose bortezomib on bone formation in smouldering multiple myeloma.
    Hildebrandt GC; Berno T; Gurule A; Mohan M; Yoon D; Salama M; Zangari M
    Br J Haematol; 2019 Jan; 184(2):308-310. PubMed ID: 29574687
    [No Abstract]   [Full Text] [Related]  

  • 20. Should high risk smoldering myeloma be treated outside a clinical trial: NO.
    Gertz MA; Vaxman I
    Leuk Lymphoma; 2021 Nov; 62(11):2565-2567. PubMed ID: 34261405
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.